Drug
Efpeglenatide clinical trials
Also written HM11260C.
Keep track of what changes. Save the efpeglenatide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2017 | 1 |
| 2018 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Hypoglycemic Agents source
Studies
Open first, then newest update. How each study uses efpeglenatide is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinRecruitingPhase 3Hanmi Pharmaceutical Company LimitedNCT07379333Written as HM11260C
- A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusCompletedPhase 3Hanmi Pharmaceutical Company LimitedNCT06174779Written as HM11260C
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseCompletedPhase 3Hanmi Pharmaceutical Company LimitedNCT03353350Written as efpeglenatide (SAR439977)
- Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminTerminatedPhase 3SanofiNCT03684642Written as Efpeglenatide
- Effect of Efpeglenatide on Cardiovascular OutcomesTerminatedPhase 3SanofiNCT03496298Written as Efpeglenatide (SAR439977)
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02057172Written as HM11260C
- Effect of LAPS-Exendin on Body Weight in Obese PopulationCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02075281Written as HM11260C
- Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02081118Written as HM11260C
- Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT01452451Written as HM11260C
- A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusStatus unknownPhase 1Hanmi Pharmaceutical Company LimitedNCT02059564Written as HM11260C
- A Study of HM11260C in Healthy Male SubjectCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01093729Written as HM11260C
Codes
What other systems call efpeglenatide · ClinicalTrials.gg INT001379
- MeSH (NLM) C000709212efpeglenatideOne source NLM
- UNII (FDA) 3M1V5Z2270EFPEGLENATIDEConfirmed FDA, NLM
- NCI Thesaurus C166682EfpeglenatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709212 | efpeglenatide | One source NLM |
| UNII (FDA) | 3M1V5Z2270 | EFPEGLENATIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C166682 | Efpeglenatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.